

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450

Date of Signature and Deposit: February 14, 2007


Sara D. Vinarov

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alan D. Attie
Donald L. Gillian-Daniel
Paul W. Bates

Date: February 14, 2007

Serial No.: 09/620,820

Group Art Unit: 1636

Filed: July 21, 2000

Examiner: Celine X. Qian

Title: INHIBITION OF LIPOPROTEIN SECRETION

File No.: 960296.97290

Confirmation No.: 4397

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner For Patents
P O Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Enclosed is a completed PTO Form 1449 listing additional documents that the applicants in the above-identified application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application.

A fee in the amount of \$180.00 is believed due in connection with this submission.


Please charge the fee to Deposit Account No. 17-0055.

Respectfully submitted,


Sara D. Vinarov
Reg. No. 48,524
Attorney for Applicants
QUARLES & BRADY LLP
P O Box 2113
Madison, WI 53701-2113

02/20/2007 HGUTEMAI 00000018 170055 09620820
01 FC:1806 180.00 DA

TEL 608/251-5000
FAX 608/251-9166



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	09/620,820
Filing Date	07/21/2000
First Named Inventor	Alan D. Attie
Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	960296.97290

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BRAUN, A., et al., "Loss of SR-BI Expression leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease...", Cir. Res. 90:270-276 (2002)	
		BRESLOW, J.L., et al., "Transgenic Mouse Models of Lipoprotein Metabolism and Atherosclerosis," Proc. Natl. Acad. Sci. USA 90:8314-8318 (1993)	
		CLEE, S.M., et al., "The Genetic Landscape of type 2 Diabetes in Mice," Endocrine Reviews 28:48-83 (2007)	
		DE WINTHER, M.P.J., et al, "New mouse models for lipoprotein metabolism and atherosclerosis," Current Opinion in Lipidology 13:191-197 (2002)	
		GRASS, D.S., et al, "Transgenic mice expressing both human apolipoprotein B and human CETP...", Journal of lipid Research 36:1082-1091 (1995)	
		HERRERA, V.L.M., et al., "Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival...", Nature medicine 5:1383-1389 (1999)	
		MARSCHANG, P., et al., "Mouse models as tools for dissecting disorders of lipoprotein metabolism," Cell & Developmental Biology 14:25-35 (2003)	
		MASUCCI-MAGOULAS, L., et al., "A mouse model with features of familial combined hyperlipidemia," Science 275:391-394 (1997)	
		MELMAN, A., et al., "hMaxi-K Gene Transfer in Males with Erectile Dysfunction: Results of the First Human Trial," Human Gene Therapy 18:1165-1176 (2006)	
		SHARPLESS, N.E., et al., "The mighty mouse: genetically engineered mouse models in cancer drug development," Nature Rev. Drug Discovery 5:741-754 (2006)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

445544



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/620,820
Filing Date	07/21/2000
First Named Inventor	Alan D. Attie
Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	960296.97290

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TAKAHASHI, H., et al, "Effect of CETP on the Plasma Lipoprotein Profile in Four Strains of Transgenic Mouse," Biochemical and Biophysical Res. Com. 283:118-123 (2001)	
		ZHANG, S., et al., "Diet-Induced occlusive Coronary Atherosclerosis, Myocardial Infarction...", Circulation 111:3457-3464 (2005)	
		KAHLE, P.J., et al., "The emerging utility of animal models of chronic neurodegenerative diseases," Emerging Therapeutic Targets 5:125-132 (2001)	
		WARRINGTON K.H., Jr., et al., "Treatment of human disease by adeno-associated viral gene transfer," Hum Genet 119:571-603 (2006)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.